Adeline Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.70 Cr
as on 03-12-2024
- Paid Up Capital ₹ 7.51 Cr
as on 03-12-2024
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 38.00 Cr
as on 03-12-2024
About Adeline Pharmaceuticals
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.70 Cr and a paid-up capital of Rs 7.51 Cr.
The company currently has active open charges totaling ₹38.00 Cr.
Narasaiah Arigela, Pearl Gomes, and Desmond Gomes serve as directors at the Company.
- CIN/LLPIN
U51397WB2022PTC252369
- Company No.
252369
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2022
- Date of AGM
04 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Adeline Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Desmond Gomes  | Managing Director | 21-Mar-2022 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Narasaiah Arigela | Director | 09-Jan-2024 | Current |
| Pearl Gomes | Director | 21-Mar-2022 | Current |
Financial Performance of Adeline Pharmaceuticals.
Adeline Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Adeline Pharmaceuticals?
In 2023, Adeline Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
New Viswabharathy Drug Lines Private LimitedActive 2 years 7 monthsNarasaiah Arigela is a mutual person
- Prime Time Logistics Technologies Private LimitedActive 33 years 8 months
Narasaiah Arigela is a mutual person
- Sri Venkateswara Galaxy Medical Distributors Private LimitedActive 3 years 16 days
Narasaiah Arigela is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Aug 2023 | ₹38.00 Cr | Open |
How Many Employees Work at Adeline Pharmaceuticals?
Unlock and access historical data on people associated with Adeline Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adeline Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adeline Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
